In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The prognostic role of late gadolinium enhancement in patients with aortic stenosis: a systematic review and meta-analysis

Session Poster Session 2

Speaker Christos Papanastasiou

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease - Epidemiology, Prognosis, Outcome
  • Session type : Poster Session
  • FP Number : P1129

Authors : C Papanastasiou (Thessaloniki,GR), D Kokkinidis (New York,US), P Kampaktsis (New York,US), I Bikakis (Athens,GR), D Cunha (Iowa City,US), E Oikonomou (Athens,GR), J Greenwood (Leeds,GB), M Garcia (New York,US), T Karamitsos (Thessaloniki,GR)

C Papanastasiou1 , D Kokkinidis2 , P Kampaktsis3 , I Bikakis4 , D Cunha5 , E Oikonomou6 , J Greenwood7 , M Garcia8 , T Karamitsos1 , 1Ahepa University Hospital, 1st Cardiology Department - Thessaloniki - Greece , 2Albert Einstein College of Medicine, Department of Medicine - New York - United States of America , 3Weill Cornell Medical College, Department of Medicine - New York - United States of America , 4401 Army General Hospital of Athens - Athens - Greece , 5University of Iowa, Department of Radiology - Iowa City - United States of America , 6University of Athens Medical School - Athens - Greece , 7University of Leeds, Leeds Institute for Cardiovascular and Metabolic Medicine - Leeds - United Kingdom of Great Britain & Northern Ireland , 8Albert Einstein College of Medicine, Division of Cardiology - New York - United States of America ,


Background: Myocardial fibrosis is a common feature of many cardiac diseases. Cardiac magnetic resonance (CMR) has the ability to non-invasively detect regional fibrosis, using the LGE technique. Several studies have explored whether LGE is associated with adverse outcome in patients with AS.

Purpose: The aim of this systematic review was to explore the prognostic value of late gadolinium enhancement (LGE) in patients with aortic stenosis (AS).

Methods: Electronic databases were searched to identify studies investigating the ability of LGE to predict all-cause mortality in patients with AS. A random effects model meta-analysis was conducted. Heterogeneity was assessed with I2.

Results: Six studies comprising 1,250 patients met our inclusion criteria. LGE was present in 45.3% of patients. In the pooled analysis, LGE was found to be a strong univariate predictor of all-cause mortality (pooled unadjusted OR: 2.28, 95% CI: 1.27 to 4.09, I2=61%). Four of the included studies reported adjusted HR for mortality. LGE was independently associated with mortality, even after adjusting for baseline characteristics (pooled adjusted HR: 2.50, 95% CI: 1.64 to 3.83, I2=0%).

Conclusion: Fibrosis on LGE-CMR is a powerful predictor of all-cause mortality in patients with AS and may serve as a novel marker for risk stratification. Future studies should explore whether LGE-CMR can also be used to optimize timing of AS-related interventions.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are